Aurora Cannabis reports Q1 revenue C$98M vs. C$83.4M last year

Reports Q1 adjusted EBITDA C$10.8M vs. C$3.5M last year. “We delivered another strong quarter of sustained, profitable growth, driven by disciplined execution of our strategy. Global medical cannabis net revenue1 rose 37%, supported by 85% growth in international markets, most notably Germany and Poland, alongside growth in Canadian medical cannabis and record contributions from our plant propagation business. These top-line gains were supported by more than 200% growth in adjusted EBITDA, and 42% growth in positive free cash flow,” said Executive Chairman and Chief Executive Officer Miguel Martin. “Our performance highlights the competitive distinction of our platform. International medical cannabis our highest-margin segment now accounts for 57% of our global medical cannabis net revenue. Bevo, our plant propagation business, which diversifies our revenue streams beyond cannabis, added further momentum through seasonal strength and continued organic expansion. And for the second consecutive year, we expect to generate positive annual free cash flow, reinforcing our operational execution and differentiation from peers,” concluded Martin.